 Akebia Therapeutics, Inc. Nasdaq: AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results for the second quarter ended June 30, 2020 on Monday, August 10, 2020. In lieu of a second quarter financial results and business update call, Akebia management plans to host a conference call and webcast in early September to report top-line data from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs. The two PRO2TECT studies, which have progressed through database lock, evaluated the efficacy and safety of vadadustat, Akebias investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor HIF-PHI, versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease CKD in 3,513 adult patients not on dialysis. 